Investigations of Hydrazine Cleavage of Eltrombopag in Humans

被引:9
作者
Deng, Yanli [1 ]
Rogers, Martin [1 ]
Sychterz, Caroline [1 ]
Talley, Kimberly [1 ]
Qian, Yanwen [1 ]
Bershas, David [1 ]
Ho, May [1 ]
Shi, Wei [1 ]
Chen, Emile P. [1 ]
Serabjit-Singh, Cosette [1 ]
Gorycki, Peter D. [1 ]
机构
[1] GlaxoSmithKline, Dept Drug Metab & Pharmacokinet, King Of Prussia, PA 19406 USA
关键词
INTESTINAL MICROFLORA; METABOLISM; PHARMACOKINETICS; DIGOXIN; LEVOSIMENDAN; DISPOSITION; ANIMALS; DRUGS; FLORA; SITE;
D O I
10.1124/dmd.111.040188
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
After oral administration to humans, eltrombopag undergoes extensive cleavage of its hydrazine linkage to metabolites, which are exclusively eliminated in urine. In vitro, the cleavage pathway was not detected in systems using cytochrome P450 enzymes, renal or hepatic microsomes, or hepatocytes but was readily evident after anaerobic incubation with rodent cecal contents or human fecal homogenate. Antibiotic treatment in vitro and in vivo inhibited eltrombopag cleavage, further indicating that cleavage is via gut microbes. Antibiotic treatment did not alter the systemic exposure of eltrombopag in mice. Oral and intravenous pharmacokinetic characterization in the mice with one of the cleavage products indicated that it was readily absorbed, conjugated, and eliminated in urine, consistent with its fate after oral administration of eltrombopag. Variation in this microbial pathway, for example by antibiotic cotherapy, is unlikely to be clinically significant.
引用
收藏
页码:1747 / 1754
页数:8
相关论文
共 24 条
[1]   Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators [J].
Antila, S ;
Pesonen, U ;
Lehtonen, L ;
Tapanainen, P ;
Nikkanen, H ;
Vaahtera, K ;
Scheinin, H .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 23 (03) :213-222
[2]   Site dependent bioavailability and metabolism of levosimendan in dogs [J].
Antila, S ;
Huuskonen, H ;
Nevalainen, T ;
Kanerva, H ;
Vanninen, P ;
Lehtonen, L .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 9 (01) :85-91
[3]   The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[4]   Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura [J].
Bussel, James B. ;
Cheng, Gregory ;
Saleh, Mansoor N. ;
Psaila, Bethan ;
Kovaleva, Lidia ;
Meddeb, Balkis ;
Kloczko, Janusz ;
Hassani, Habib ;
Mayer, Bhabita ;
Stone, Nicole L. ;
Arning, Michael ;
Provan, Drew ;
Jenkins, Julian M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2237-2247
[5]   Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects [J].
Deng, Yanli ;
Madatian, Armina ;
Wire, Mary Beth ;
Bowen, Carolyn ;
Park, Jung Wook ;
Williams, Daphne ;
Peng, Bin ;
Schubert, Ernest ;
Gorycki, Frances ;
Levy, Mark ;
Gorycki, Peter D. .
DRUG METABOLISM AND DISPOSITION, 2011, 39 (09) :1734-1746
[6]  
DOBKIN JF, 1983, SCIENCE, V220, P325
[7]   Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion [J].
Eriksson, UG ;
Dorani, H ;
Karlsson, J ;
Fritsch, H ;
Hoffmann, KJ ;
Olsson, L ;
Sarich, TC ;
Wall, U ;
Schützer, KM .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) :775-782
[8]  
Fouda HG, 1997, DRUG METAB DISPOS, V25, P140
[9]   INTESTINAL MICROFLORA - METABOLISM OF DRUGS AND CARCINOGENS [J].
GOLDIN, BR .
ANNALS OF MEDICINE, 1990, 22 (01) :43-48
[10]   MEASUREMENT OF URINARY DIGOXIN AND DIHYDRODIGOXIN BY RADIOIMMUNOASSAY AND BY MASS-SPECTROSCOPY [J].
GREENWOOD, H ;
SNEDDEN, W ;
HAYWARD, RP ;
LANDON, J .
CLINICA CHIMICA ACTA, 1975, 62 (02) :213-224